Her2t Genetic Tags for Stable Transgene Selection and Tracking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies face challenges in achieving stable and high-level expression of transgenes in cells, limiting the clinical success and reproducibility of gene therapy strategies.
Innovation Solution
The use of a genetic tag, Her2t, which is devoid of intracellular components but contains the Her2 transmembrane region and a conformationally intact epitope recognized by trastuzumab, allows for the ex vivo selection and purification of homogenous populations of cellular therapeutics expressing a transgene of interest, and can be used to track these cells in vivo.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional gene transfer methods are used, then transgene expression can be achieved, but stable expression at levels comparable to endogenous genes cannot be obtained
Solution Approach 1:
The invention segments the transgene expression system by introducing a separate genetic tag (HER2t) that is distinct from the transgene of interest. This tag is expressed at high levels and serves as a selectable marker, allowing independent optimization of transgene expression while maintaining stable integration through the lentiviral vector system.
Solution Approach 2:
The genetic tag HER2t acts as an intermediary element between the lentiviral vector and the transgene. It provides a detectable and selectable surface marker that mediates the selection process, enabling identification and purification of cells with stable transgene expression without directly affecting the transgene itself.
2Ease of operation
If genetic tags are introduced for cell selection, then ex vivo selection and purification can be achieved, but the genetic payload increases
Solution Approach 1:
The invention extracts only the necessary functional elements for selection from the full HER2 protein. Specifically, it uses the extracellular domain (amino acids 511-652) as the genetic tag, omitting the intracellular signaling components. This extraction provides sufficient surface expression for selection while minimizing the genetic burden on the cell.
Solution Approach 2:
The genetic tag is designed with localized functionality - the extracellular domain provides the necessary surface marker properties for selection, while the transmembrane region ensures proper membrane localization. This local quality approach ensures the tag performs its selection function without requiring the full complement of HER2 protein functions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Her2t enables the efficient purification and tracking of transgene-expressing cells, enhancing the therapeutic reach of CAR therapy by allowing for the concerted purification of cells expressing multiple transgenes, thereby improving the stability and efficacy of gene therapy.
Implementation Method 1
Her2t is devoid of all Her2 intracellular components, yet contains the Her2 transmembrane region, a conformationally intact epitope recognized by the monoclonal antibody trastuzumab (Herceptin)
Data Source
AI summary
Embodiments of the disclosure include methods of manufacturing compositions comprising host cells. In some alternatives, a method comprises introducing into a host cell an isolated nucleic acid, such as a nucleic acid coding for an isolated polypeptide of an extracellular domain (ECD) of HER2 polypeptide. Some embodiments include culturing the host cells in a medium comprising at least one growth factor. Some embodiments include selecting the host cells for expression of ECD.